Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. NTRK Fusion Gene Positive Advanced Solid Tumour market , by Region, 2018-2027 (USD Billion)
1.2.2. NTRK Fusion Gene Positive Advanced Solid Tumour market , by Type, 2018-2027 (USD Billion)
1.2.3. NTRK Fusion Gene Positive Advanced Solid Tumour market , by end user, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Dynamics
3.1. NTRK Fusion Gene Positive Advanced Solid Tumour market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Growing Research and Development Activities
3.1.3. Increasing Prevalence of Cancer
3.1.4. Market Challenges
3.1.5. Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes
3.1.6. Market Opportunities
3.1.7. technical advancements in the tumour treatment
Chapter 4. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Industry Analysis
4.1. Porters 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porters 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , by Type
5.1. Market Snapshot
5.2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by Type , Performance - Potential Analysis
5.3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Estimates & Forecasts by Type 2017-2027 (USD Billion)
5.4. NTRK Fusion Gene Positive Advanced Solid Tumour market , Sub Segment Analysis
5.4.1. By Therapeutics
5.4.2. By Diagnostics
Chapter 6. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , by End user
6.1. Market Snapshot
6.2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by End user, Performance - Potential Analysis
6.3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Estimates & Forecasts by End user 2017-2027 (USD Billion)
6.4. NTRK Fusion Gene Positive Advanced Solid Tumour market , Sub Segment Analysis
6.4.1. Hospitals and Clinics
6.4.2. Cancer Centers
6.4.3. Others
Chapter 7. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , Regional Analysis
7.1. NTRK Fusion Gene Positive Advanced Solid Tumour market , Regional Market Snapshot
7.2. North America NTRK Fusion Gene Positive Advanced Solid Tumour market
7.2.1. U.S. NTRK Fusion Gene Positive Advanced Solid Tumour market
7.2.1.1. Type breakdown estimates & forecasts, 2017-2027
7.2.1.2. End user breakdown estimates & forecasts, 2017-2027
7.2.2. Canada NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3. Europe NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.3.1. U.K. NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.2. Germany NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.3. France NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.4. Spain NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.5. Italy NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.6. Rest of Europe NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.4.1. China NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.2. India NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.3. Japan NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.4. Australia NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.5. South Korea NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.6. Rest of Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumour market
7.5. Latin America NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.5.1. Brazil NTRK Fusion Gene Positive Advanced Solid Tumour market
7.5.2. Mexico NTRK Fusion Gene Positive Advanced Solid Tumour market
7.6. Rest of The World NTRK Fusion Gene Positive Advanced Solid Tumour market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Bayer AG
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Teva Pharmaceuticals
8.2.3. Empire Genomics, LLC.
8.2.4. SeraCare Life Sciences
8.2.5. F. Hoffmann-La Roche Ltd
8.2.6. NeoGenomics Laboratories, Inc.
8.2.7. Glaxosmithkline plc
8.2.8. Merck & Co.
8.2.9. Daiichi Sankyo Company Limited
8.2.10. S Deciphera Pharmaceuticals, Inc.

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption